12:00 AM
 | 
Oct 08, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Eliglustat tartrate: Phase III data

The double-blind, international Phase III ENGAGE trial in 39 evaluable patients showed that twice-daily eliglustat tartrate met the primary endpoint of reducing spleen volume from baseline to 9 months vs. placebo (28% vs. a 2% increase, p<0.0001). Sanofi's Genzyme Corp. unit also said that eliglustat tartrate met all secondary endpoints, including improving hemoglobin levels, platelet levels and...

Read the full 271 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >